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Acetate
relaxation of isolated vascular smooth muscle 39
Acid-base
balance, H + secretion in renal cortical tubules 136
Acidification during endocytosis 23:S-184
Acidosis
azotemia, branched-chain amino acid catabolism 808
bicarbonate HD, weight gain 22:S-174
Acute cellular rejection, lymphs (abst) 615
Acute renal failure
age, GN, renal biopsy (abst) 426
calcium entry blockers 313
diethylene glycol (abst) 619
glycerol induced 22:S-l 13
hantavirus disease in Africa (abst) 603
hyperalimentation, amino acid 22:S-72
hyperkalemia, heart transplantation (abst) 625
insulin metabolism 22:S-l04
ischemic, ANP infusion (abst) 436
leukocyte proteinases 22:S-l00
malarial origin in human kala-azar (abst) 606
malnutrition 22:S-167
mercury induced 246
prostacyclin on postischemic 479
proteases, catabolic factors in 22:S-94
protein prior to renal ischemia 22:S-76
solute transport in CAPD, new treatment 562
Acute tubular necrosis, CyA (abst) 625
Acute volume expansion, chloride 238
Adenosine
hypoxemia-induced decrease of GFR (abst) 437
Adenosine triphosphate
soluable 5'-nucleotidase (abst) 435
intracellular Ca (abst) 627
Adenylate cyclase
vasopressin-sensitive, subunit interactions 23: S-43
Adenylyl cyclase, G proteins 23:S-l4
ADH
captopril inhibits hydroosmotic effect of 844
Adriamycin-induced nephropathy (abst) 627
Adult polycystic disease
DNA markers (abst) 772
intensive follow-up (abst) 774
mutations in the LDL gene 23:S-156
trimethoprim-sulfamethoxazole in cyst fluid 883
Age
results of regular dialysis (abst) 607
signal transduction of G proteins 23:S-38
Agonist, Ca signalling in cells 23S-68
Albumin
cationic in MCN 547
MCN, renal selectivity properties towards 69
Albuminuria
epithelial cell structure 736
Aldosterone
salt, volume and hypertension 590
Alkaline phosphatase, CyA (abst) 431
Alkalosis
isovolemic hemofiltration in dog 322
metabolic, antiacid and calcium polystyrene (abst) .... 437
Allografts
vascular lesions (abst) 432
Alpha adrenoceptor agonist
arterial hypotension in chronic hemodialysis 728
Alpha ketoanalogs, uremia 22:S-l86
Aluminum
gastrointestinal absorption of, uremia 821
hemodialysis and hyperaluminemia 710
hydroxide, iron gastrointestinal absorption (abst) 622
phosphate binding (abst) 432
related osteomalacia, reverse osmosis 96
vitamin D3 receptors, endorgan response 204
Alveolar gas exchange (abst) 620
Amiloride
molecular properties of action, Na transport tar-
gets 785
salt, volume and hypertension 590
Amino acid
abnormal metabolism in CRF 22:S-18l
branched chain, catabolism and acidosis 808
CAPD, protein and energy levels 22:S-136
CRF and ketoacids 123
erythrocyte, plasma ammonium levels 22:S-l97




nutrition in hypertrophy of renal tissue 22:S-2
Sulfur, maintenance HD 22:S-191
Aminonucleoside nephrosis
dietary cholesterol supplementation 671
enhancement by administration of protamine 691
Ammonium levels
erythrocyte amino acids 22:S-l97
Amyloid arthropathy, CRF (abst) 624
Amyloidosis and hydatid disease (abst) 608
AN-69 plate filter, HD (abst) 777
Analbuminemic rats, furosemide 198
Analysis, target, adenylate cyclase 23:S-43
Anaphylatoxin generation, blood cooling 907
Anaphylaxis, antigen responses 233
Anderson-Fabry's disease (abst) 437
Anemia
xx
deferoxamine in HD (abst) 621
erythropoiesis, transplantation 526
hemodialysis and hyperaluminemia 710
HUS and TTP 292
in HD patients (abst) 614
Angiotensin
thirst and the renin- 21 :S-27
Angiotensin converting enzyme
captopril, hydroosmotic effect of ADH 844
inhibition, reduction of proteinuria 78
ontogenesis of ACE 684
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Angiotensin II
calcium in concentration (abst) 628
regulation of papillary plasma flow 472
thirst and the renin-angiotensin system 21:S-27
Anhydrosis, sweat secretion 21:S-102
Anion
exchange proteins in the kidney 23:S-129
transport 23:S-117
Anti-rat thymocyte serum, cell damage 514
Antibiotics




composition of crescents in human GN 284
down modulation of Heymann's nephritis, HgCI2 227
epithelial antigens, GBM (abst) 774
IgA nephropathy (abst) 426, 627
induced mesangial cell damage 514
monoclonal, immunosuppressants on T cell acti-
vation 362
monoclonal, T cells and macrophages in RPGN 868
polyclonal, sodium pump regulation 23:S-113
removal of subepithelial immune complexes 13
Anticoagulation, HD (abst) 622
Antidiuretic hormone
aging effect on vasopressin action 21 :S-90
cellular events in vasopressin action 21 :S-56
hyponatremia 21: S-67
Antidiuretic hormone
lithium clearance during natriuresis 376
morphological aspects of the action of 21:S-51
regulation of water metabolism in nephrotic chil-
dren 21:S-83
removal during HF stimulates its secretion (abst) 428
water metabolism in historical perspectives 21:S-l13
Antigen
f32M significance in evaluation of renal function 635
fibrinolysis 280
mediated process, complement activation in IgA
nephropathy 837
removal of subepithelial epithelial immune com-
plexes 13
renal anaphylaxis in perfused kidney 233
Antiinflammatory drugs, prostaglandin 1
Antiporter
Na/H, genetic approach 23:S-144




Arterial calcification in ESRD 388
Arteriolar cell cultivation (abst)
Arterioles, afferent, ANF and rerun 493
Ascites and cirrhosis (abst) 626
Asymmetric septal hypertrophy (abst) 626
Atherosclerosis
LDL receptor mutations 23:S-l56
Atrial natriuretic factor
renin release in isolated afferent arterioles 493
Atrial natriuretic peptide
All and PAF (abst) 628
catecholamines during ischemic ARF (abst) 436
cirrhosis (abst) 628
in renal failure, dialysate (abst) 434
indomethacin and sodium handling 774
ischemic ARF (abst) 436
mineralocorticoid or glucocorticoid excess (abst) 435
norepinephrine infusion (abst) 436
plasma levels and dialysance in terminal renal
failure 554
site of action in humans 537
sodium handling of essential hypertension (abst) 773




anti-lymphocyte globulin, transplantation (abst) 610
CyA, graft histology (abst) 777
Azotemia
vitamin B-6 deficiency 22:S-l62
diuretic-induced 47
loop diuretics in CR1 572
renal handling of urea 721
Backflux of H, tubular epithelium 136
Bacterial clearance in renal failure 678
Bacteriuria
in Algiers (abst) 604
in Ismailia (abst) 608
Bartter's syndrome
diluting segment reabsorption (abst) 773
Basement membrane proteoglycans 498
Basement membranes in cystic disease 187
Bence Jones protein toxicity 850
Beta blocker
CAPD (abst) 618
no antihypertensive effect (abst) 775
Beta2-adrenergic receptor
homology with rhodopsin 23:S-2
Beta2-microglobulin
significance in evaluation of renal function 635
Bicarbonate
acetate in hemodialysis 39
reabsorption, metabolic alkalosis, hemofiltration 322
Binding, Na,K,Cl-cotransport system 23: S- 134
Biopsy
epidemiology of idiopathic glomerular disease 112




cooling effect on anaphylatoxin generation 907
flow, metabolic transport 22:S-9
gas, cuprophan reuse 117
hemodialysis ineffective in coagulation defects
(abst) 606
peripheral morphology diagnosis of rejection
(abst) 603
Blood pressure
ACE inhibition, proteinuria 78
dietary lipids in subtotal nephrectomy 335
exercise ameliorates PGN 815
K influence on 22:S-242
salt, volume and hypertension 590
sodium sensitivity and resistance 22:S-234
Blood-membrane, hemodialysis, cytokine 84
Bone
acidosis and BCAA catabolism 808
Al accumulation in uremics (abst) 620
XXII Subject Index: Vol. 32
Al related osteomalacia, reverse osmosis 96
alkaline phosphatase in patients on CyA (abst) 431
calcitriol treatment for osteodystrophy in children 89
keto acid supplements, nutrition, uremic patients. . . . S-170
marrow, IgA nephropathy (abst) 774
microanalytic study (abst) 611
vitamin D and renal osteodystrophy 911
vitamin D and skeletal resistance to PTH 801
Brain mechanisms and drinking 21:S-35
Brush border membrane, cations (abst)
Bumetanide
furosemide, loop diuretics in CR1 572
binding, Na,K,Cl-cotransport 23:S- 134, S-141
C-terminus peptides, synthetic 23:S-162
Cadmium poisoning, f32M 635
Calcification microanalysis (abst)
Calcification, arterial in ESRD 388
Calcitonin
calcium regulating hormones and the kidney 760
Calcitriol
high dose controls osteodystrophy in children 89
Calcium
adenosine and intracellular (abst) 627
All and cultured glomerular mesangial cells (abst) .... 628
defects in hypertension, PTH (1—34) 22:S-249
ischemic ARF 313
Mg + inhibits stones(abst) 603
oxalate stone disease, GFR 749
phosphate vitamin D and PTH in uremics (abst) 619
regulating hormones and the kidney 760
signalling in cells 23:S-68
vitamin D and renal osteodystrophy 911
vitamin D and skeletal resistance to PTH 801
cAMP
132-adreneric structure and function 23:S-8
cellular events in vassopressin action 21:S-56
Cancer
tumoral factors on cAMP production, transport
(abst) 435
nitrosodimethylamine in CRF 22:S-l59
CAPD
Algerian experience (abst) 604
alternative: 3 exchanges/day (abst) 615
betablockers (abst) 618
/32-microglobulin effect on (abst) 432
ceftriazone (abst) 438
circulating maltose, isomaltose 22:S-210
diabetics (abst) 618
in Algiers (abst) 608
multicenter registry (abst) 622
peritoneal cavity lymphatic absorption 165
peritoneal effluent (abst) 618
protein, amino acids, energy levels in 22:S-136
serum magnesium level and arterial calcification
in ESRD 388
solute transport, new treatment for ARF 562
technical developments (abst) 432
vs. HD in diabetics (abst) 613
Captopril
ADH in CCT, hydroosmotic effect 844
CE! and progressive GN 794
diabetic nephropathy (abst) 776
GFR, blood flow in essential hypertension (abst) 614
Carbohydrate
receptors, glycoprotein endocytosis 23:S-167
Cardiac
function, HD vs. HF 399
hypertrophy, secondary hyperparathyroidism, he-
modialysis 899
Cardiovascular
effects in HD (abst) 620
molecular properties of amiloride action 785
vasopressin antagonists 21 :S-76
pre-eclampsia in pregnancy, case study 151
Carnitine
L-carnitine in CRF 22:S-132
metabolism, CRF 22:S-1 16
precursor 6-N-trimethyllysine, HD 22:S-128
Carpal tunnel syndrome
hemodialysis (abst) 427, 617
Catabolism, protein regulation 22:S-81
Catecholamine
in CRF patients on HD 427
secretion, hypertension 590
Cathepsin B and L, nephrosis 354
Cation
albumin in MCN 547
organic in BBMV (abst) 435
transport in erythrocytes from uremic patients 256
Caval constriction, saline infusions 488
Cavity lymphatic absorption in dialysis 165
cDNA, anion transport 23:S-117
Ceftriazone in CAPD (abst)
Cell
calcium signalling in 23:S-68




growth, CRF before and after transplantation
(abst) 438
high dose calcitriol in osteodystrophy 89
hormonal regulation of water metabolism,
nephrotic 21:S-83
mesangial changes in IgA nephropathy 585
Chloride
GFR in acute volume expansion 238
metabolic alkalosis, isovolemic hemofiltration 322
Cholesterol
LDL receptor mutations 23:S-l56
supplementation, nephrosis 671
Chronic kidney disease in Turkey (abst) 604
Chronic renal failure
abnormal amino acid metabolism 22:S-l8l
after nephrotoxic nephritis 173
anemia, L-carnitine and sodium transport 754
apolipoprotein profile in patients 368
BCAA and acidosis, azotémia 808
carnitine metabolism 22:S-1l6
causes, presentation and outcome in Khartoum
(abst) 608
circulating maltose, isomaltose 22:S-2l0
desferoxamine induced neurotoxicity (abst) 624
diabetes control and 22:S-53
dietary protein restriction and 22:S-49
fasting, fatty acid utilization in uremia 22:S-l45
gastric flora and emptying rate (abst) 606
growth in children (abst) 438
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ketoacid treatment following amino acids 123
ketoacids, low protein diet, CRF progression 22:S-67
L-carnitine supplementation 22:S-132
leukocyte proteinases, catabolism of ARF 22:S-100
nitrosodimethylamine modulation 22:S-159
rate of progression in 167 cases (abst) 429
serum apolipoprotein profile 368
serum thyroid hormones (abst) 605
skeletal resistance to PT}TI in CRF 801
Thick ascending limb, GFR and kidney mass 22:S-57
uremia, hypercoagulable (abst) 615
Chronic renal insufficiency
comparison of loop diuretics 572
protein loading and GFR 22:S-25
retarding progression of renal disease 22:S-35
solitary kidney, protein and GFR 22:S-29
Circulation
mTC-MAG3, plasma flow (abst) 775
computer modeling (abst) 433
papillary plasma flow, All 472
Cirrhosis
and ascites, countertransport (abst) 626
ANP, glomerular contraction (abst) 628
GFR after protein loading S-32
Clearance, inulin and PAR (abst) 437
Climate, fluid and electrolyte balance 21:S-97
Cloning
f32-adrenergic receptor 23:S-2
band 3 related cDNAs from kidney 23:S-1 17
G protein, signal transduction 23:S-14
Complement
activation, IgA nephropathy 837
Concentrating mechanism, renal 21:S-43
Concentration of urine, hot climate 21:S-97
Congestive heart failure
captopril and hydroosmotic effect of ADH 844
Converting enzyme inhibition
progressive GN in rat 794
Cortex
arteriolar smooth muscle cells from, cultivation
(abst) 428
Cortical collecting tubule
captopril, hydroosmotic effect of ADH 844
H secretion 136
Corticotropin releasing factor, thirst 21:S-14
Creatinine
Algiers survey, body size and excretion of (abst) 605
Crescentic glomerulonephritis 408
Crescents
composition in human glomerulonephritis 284
GN and lung purpura 408
Cuprophan
induced anaphylatoxin generation, blood cooling 907
reuse, lung diffusion capacity 117
reuse and pulmonary function (abst) 777
Cyclophosphamide in MGN 579
Cyclosporine
blood levels, function of graft (abst) 438
blood transfusions and HLA in transplantation
(abst) 625
erythropoiesis following renal transplantation 526
G in transplantation (abst) 431
glomerular hemodynamics, hormonal participation 19
graft histology, AZA (abst) 777
in minimal change nephrotic syndrome (abst) 614
interactions with other drugs (abst)
kidney transplantation in Egypt (abst)
OKT3 mediated T cell activation
pancreas transplantation (abst)
platelet aggregation
switch to AZA after transplantation (abst)
three years use in transplantation (abst)
Cyst
endotoxin provocation in experimental cystic dis-
ease 329
glomerulosclerosis in mice transgenic for SV4O 827
trimethoprim-sulfamethoxazole in fluid, ADPKD 883
viscoelastic properties of basement membranes in
disease 187
Cystic fibrosis
transport processes in eccrine sweat gland 21:S-l09
Cystic renal disease
glomerulosclerosis, SV4O 827
Cytokine, hemodialysis, blood-membrane 84
DDAVP in uremic trombopathy (abst) 623
Deferoxamine
HD with anemia (abst) 621
Dehydration
brain mechanisms 21:S-35
fluid and electrolyte balance in hot climate 21 :S-97
Desensitization, 2-adrenergic receptor 23:S-2
Dexamethasone, hypertension 590
Diabetes
CAPD vs. RD (abst) 613
CAPD, 3 systems (abst) 618
control, effect on progression of renal failure 22:S-53
estimation of mean glomerular volume 929
hyperglycemia, glycosuria 895
hypocalcemia (abst) 615
insulin effect on sodium, water handling (abst) 605
integrated treatment with dialysis (abst) 613
nephropathy, captopril and ambuminuria (abst) 776
non-enzymatic glycation, altered renal structure 664
renal transplantation (abst) 612
retarding the progression of renal disease 22:S-35
Diabetes insipidus
distal tubular acidosis in nephritis (abst) 427
Diabetes mellitus
apolipoprotein profile of CRF patients 368
glomerular epithelial cell structure 736
Dialysate
bicarbonate, weight gain during HD 22:S-l74
composition during RD 129
composition, intercompartmental fluid shift 267
Dialysis
anemia corrected by erythropoietin (abst) 427
asymmetric septal hypertrophy (abst) 626
blood cooling on anaphylatoxin generation 907
calcitonin and hyperparathyroidism (abst) 621
CAPD in Algiers (abst) 608
CAPD technical developments (abst)
CAPD, refractory congestive heart failure (abst)
432
426
256cation transport in erythrocytes from uremics
computer modeling (abst) 433
eosinophilia (abst) 626
eriarticular erosions of hand skeleton (abst) 434
gastrointestinal absorption of Al 821
hepatitis B vaccine (abst) 429
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integrated treatment, diabetic patients (abst) 613
L-carnitine effect on sodium transport 754
LAV/HTL VIII antibodies in transplantation
(abst) 611
lymphatics, ultrafiltration in peritoneal 219
neoplasms, time (abst) 610
paired filtration, two chamber technique (abst) 613
peritonealcavity lymphatic absorption 165
polyvalent system (abst) 607
secondary hyperparathyroidism and cardiac hy-
pertrophy 899
treatment in elderly (abst) 607
Dialyzer
ANP in terminal renal failure 554
modulation of leukopenia, thrombocytopenia
(abst) 434
Diclofenac treatment, MGN (abst)
Diet
BCAA in uremia 808
branched-chain alpha ketoanalogs in uremics 22:S-186
cholesterol supplementation, aminonucleoside
nephrosis 671
cirrhotics, GFR after protein loading 22: S-32
CRF after nephrotoxic nephritis 173
eicosanoids in experimental GN 22:S-40
erythrocyte insulin receptors, uremia 22:S-202
fasting, fatty acid utilization in uremia 22:S-145
fish oil and renal insufficiency 700
GFR, protein loading, patient with solitary kidney . 22:S-29
glucose metabolism in uremia 22:S-206
growth hormone effect on GFR and renal plasma
flow 22:S-21
hypercalciuria in infancy (abst) 611
hypertension in obesity 22:S-254
idiopathic renal stone disease, vitamin D3 434
keto acid supplements, bone metabolism, uremia . 22:S-170
lipids in subtotal nephrectomy 335
ketoacids, low protein, CRF progression 22:S-67
Na and K intake in Egypt (abst) 604
protein loading and GFR 22:S-25
protein prior to renal ischemia 22:S-76
renal failure and protein restriction 22:S-49
retarding progression of renal disease 22:S-35
statistical selection of nutritional parameters 22: S- 178
uremic toxicity and protein 22:S-62
Diethylene glycol, ARF (abst) 619
Diffuse proliferative glomerulonephritis
prognosis of segmental GN in SLE 274
Dinitrophenol IgE, anaphylaxis 233
Diuretic
amiloride action and Na transporting targets 785
comparison of loop, CR1 572
therapy, azotemia, urea appearance rate 47
DNA markers, APKD (abst) 772
Donor
complications, renal function in (abst) 627
cross match (abst) 617
unilateral nephrectomy in humans 714
Dopamine
metoclopramide and renal disease (abst) 778
Drinking and brain mechanisms 21:S-35
Eccrine sweating, physiology 21:S-l02
Eicosanoid
role in experimental GN 22:S-40
synthesis, prostaglandin 1
Eicosapentaenoic acid, CR! 700
Elastase release in dialysis (abst) 613
Electrolyte
fluid balance in hot climates 21:S-97
fluid metabolism 21:S-93
transport processes in eccrine sweat gland 21:S-109
Embryogenesis, insulin receptor 23:S-61
Enalapril
hypertensive NIDDM patients (abst) 775
Encephalopathy
hemodialysis and hyperaluminemia 710
End-stage renal disease
bicarbonate HD, weight gain 22:S-174
enhancement of aminonucleoside nephrosis by
protamine 691
experimental hypertsension and glomerulonephri-
tis 652
peritoneal cavity lymphatic absorption 165
schistosomal specific nephropathy (abst) 605
segmental glomerulonephritis in SLE 274
serum and CSF trace elements in HD (abst) 604
serum magnesium level and arterial calcification 388
transplantation at Mansoura, Egypt (abst) 603
Endocarditis, infectious (abst) 623
Endocytic vesicles, non-clathnn coated 23:S162
Endocytosis
action of ADH 21:S-51
glycoprotein, membrane receptors that mediate... 23: S- 167
molecular sorting during 23:S-184
receptor mediated 23:S-162
Endopeptidase 24.11 in kinin metabolism 507
Endosomes during endocytosis 23:S-184
Endotoxin
provocation of experimental cystic disease 329
Entry blockers, Ca in ischemic ARF 313
Enzyme
glucocorticoids modulate receptors, Na-K
ATPase activity 464
insulin action on protein synthesis 23:S-82
target analysis of vasopressin-sensitive adenylate
cyclase 23:S-43
Epidemiology of glomerular disease 112
Epithelial cell
polyanion neutralization, prostanoid production 57
Erythrocytes
amino acid, plasma ammonium levels 22:S-197
cation transport, uremic patients 256
insulin receptors, uremia 22:S-202
HD (abst) 628
Erythroid band 3 anion transport 23:S-1 17
Erythropoiesis
correction of dialysis anemia by (abst) 427
dynamics after transplantation 526
transplantation, AZA, CyA and sandimmun (abst) .... 431
Essential hypertension
ANP and altered sodium handling (abst) 773
Essential mixed cryoglobulinemia (abst) 612
Eucaryotic cell, vasopressin 2l:S-8
Evolution of water metabolism 21: S-il 3
Excretion
Algiers survey: body size and (abst) 605
mineraloxorticoids on urinary acid (abst) 432
Exercise
ameliorates progressive renal disease 815
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fluid metabolism 21:S-93
glycerol induced ARF 22:S-1 13
Extrarenal epuration, salicylate (abst) 429
Factor H, absence in MPGN (abst) 616
Familial disease
Anderson-Fabry's disease (abst) 437
Fanconi's syndrome, f32M 635
Fatty acids
thromboxane synthesis in platelets 62
Fibrin
composition of crescents in human GN 284
deposition of cross linked, in human kidney dis-
eases 102
HUS and TTP, a single entity 292
procoagulant activity 31
Fibrinolysis, plasminogen activator 280
Fibrosis
interstitial during transplantation (abst) 437
Fine needle aspiration cytology (abst) 603
Fish oil and renal insufficiency 700
Fluid
body secretion, physiology of sweat 21:S-102
electrolyte balance in hot climates 21:S-97
homeostasis, brain mechanisms 21:S-35
metabolism in exercise 21:S-93
shift, dialysate composition 267
thirst 21:S-27
Focal segmental glomerulosclerosis
dietary cholesterol supplementation 671
hypertension (abst) 612
kidney graft, hyperfiltration (abst) 612
model by AMNS administration 691
reflux nephropathy 261
Fuel utilization, energy 22:S-9
Furosemide
analbuminemic rats and hypoalbuminemic
patients 198
cation transport in erythrocytes from uremic pa-
tients 256
loop diuretics in CR1 572
G proteins, signal transduction 23:S-14
Gastric flora in CRF (abst) 606
Gastrointestinal absorption of Al 821
Gene
Na/H antiporter 23:S-144
PEPCK and insulin action 23:S-82
vasopressin biosynthesis 21:S-8
Gliadin, antibodies (abst) 426
Glomerular basement membrane
albumin in MCN 69
antigenicity in hereditary nephritis (abst) 428
thickening, diabetic nephropathy 664
antibodies to epithelial antigens 774
removal of subepithelial immune complexes 13
Glomerular deposition for XFb 102
Glomerular disease
epidemiology of idiopathic 112
Glomerular filtration rate
acute protein load effect on 22:S-25
adenosine, hypoxemia-induced decrease in (abst) 437
azotemia 721
chloride in volume expansion 238
cirrhotics, protein loading 22:S-32
estimation of mean glomerular volume in diabetes 929
exercise ameliorates progressive renal disease 815
hypercalciuria in primary struvite nephrolithiasis 749
hyperglycemia and glycosuria 895
hypertonic saline infusions, thoracic caval con-
striction 488
metabolic alkalosis, isovolemic hemofiltration 322
oral protein load in patients with solitary kidney. . . 22:S-29
site of action of ANP in humans 537
TAL, urine concentrating mechanism, kidney
mass 22:S-57




eicosanoids role in 22:S-40
experimental hypertension 652
human, monoclonal antibody analysis (abst) 622
rapidly progressive, T cells and macrophages 868
Glomerulopressin, growth hormone 22:S-21
Glomerulosclerosis
renal cysts in mice, SV4O 827
Glomerulus
human, fatty acids stimulate platelet TXB2 62
maturation of, basement membrane peoteoglycans . . . . 498
Glucose metabolism 22:S-206
Glucocorticoid
modulate renal glucocorticoid receptors 464
Gluconeogenesis
in liver and kidney 23:S-94
renal fuel utilization 22:S-9
Glycoprotein
endocytosis 23:S-167
sodium pump mechanism 23:S-97
Glycosuria, hyperglycemia 895
Goodpasture 's syndrome
lung purpura with RPGN 408
Gordon's syndrome (abst) 776
Growth
polypeptide growth factors, Na + + antiporter .. 23:S- 144
Growth factor
Na /H + antiporter, genetic approach 144
unilateral nephrectomy in humans 714
Growth hormone
amino acid induced acute rise in renal function 382
effect on GFR and renal plasma flow 22:S-21
Guanosine monophosphate, RF (abst) 436




Heart disease, hemodialysis (abst) 616
Heart failure, CAPD treatment (abst) 426
Heat, fluid metabolism in exercise 21:S-93
Hemodiafiltration
HD compared 399
paired filtration with two chamber technique
(abst) 613
Hemodialysis
acetate relaxation of isolated smooth muscle 39
alveolar gas exchange (abst) 620
amyloid arthropathy, CRF (abst) 624
anemia, DFO (abst) 614
ANP in terminal renal failure 554
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antiacid and calcium polystyrene (abst) 437
arterial hypotension 728
autonomic nervous system (abst) 618
beta 2 microglobulin (abst) 432
bicarbonate, weight gain 22:S-174
blood cooling effect on anaphylatoxin generation 907
blood-membrane in, cytokine 84
calcium carbonate and calcium gluconate and
binder (abst) 436
CAPD in Algeria (abst) 604
cardiac function 399
cardiovascular effects (abst) 620
carnitine, 6-N-Trimethyllysine and 22:S-128
carpal tunnel syndrome (abst) 427
carpal tunnel syndrome with amyloids (abst) 617
catecholamines in patients with CRF (abst) 427
cationic fluxes in erythrocytes (abst) 628
cuprophan reuse 117
dialysate composition, fluid shift 267
dialy sate compositon change 129
elastase release (abst) 613
gastrointestinal absorption of Al 821
hemoglobin stabilization buffer capacity (abst) 608
hepatitis B vaccination, zinc, seroconversion rate. 22:S-149
histamine release (abst) 427
HIV antibodies, transplantation (abst) 616
HTLV III antibodies (abst) 609
hyperaluminemia 710
ineffective in correction of blood coagulation
(abst) 606
ischemic heart disease (abst) 616
L-carnitine supplementation, CRF 22:S-132
lipid metabolism of heparin treatment (abst) 433
maintenance, sulfur amino acids 22:S-l91
membranes, PAF-acether (abst) 614
metabolic alkalosis, antiacid and calcium polysty-
rene (abst) 437
middle molecule removal (abst) 621
multicenter CAPD registry (abst) 622
nutritional 22:S- 167
osteomalacia in uremics (abst) 623
polyvalent system (abst) 607
proteases, catabolic factors in RF 22:S-94
secondary hyperparathyroidism and cardiac hy-
pertrophy 899
serum and CSF trace elements in ESRD (abst) 604
serum phosphate and Al phosphate binders (abst) 609
statistical selection, nutritional parameters 22:S-l78
symptomatic hypotension (abst) 616
thirst regulation (abst) 620
tissue plasminogen activator, fibrinolysis 280
without anticoagulation (abst) 622
Hemodialyzer
extracorporeal enzymatic heparin removal 452
Hemodynamics
ANF on renin release 493
dialysate composition, intercompartmental fluid
shift 267
mercury induced ARF 246
papillary plasma flow and All 472
regulation of renal, amino acid and hormone 22:S-lS
semichronic hypoproteinemia (abst) 776
water loading (abst) 776
Hemofiltration
ADH removal during HF stimulates its secretion
(abst) 428
AN-69 plate filter (abst) 777
metabolic alkalosis in isovolemic 322
Hemoglobin stabilization in HD (abst) 608
Hemolytic uremic syndrome
CyA enhances platelet aggregation 888
TTP 292
Heparin
basement membrane proteoglycans and matura-
tion of glomerulus 498
blood picture and lipoproteins (abst) 433
coagulation inhibitors in nephrotic syndrome
(abst) 619
extracorporeal enzymatic removal 452
treatment in HD (abst) 433
Hepatic fibrosis, schistosomal GN (abst) 605
Hepatitis
hemodialysis, after transplantation (abst) 616
vaccine in dialysis (abst) 429
Hepatocytes, 02 and methyguanidine 22:S-229
Heymann's nephritis
down modulation by mercuric chloride 227




action of ADH in transport 21:S-51
calcium regulating 760
calcium signalling 23:S-68
G proteins, signal transduction 23:S-14
effects on binding sites 23:S-l41
growth, amino acids and rise in renal function 382
growth, effect on GFR and renal plasma flow 22:S-21
insulin action on protein synthesis 23S-82
peptide, vasopressin 21 :S-8
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